Stability of furosemide in human albumin solution

被引:2
作者
Elwell, RJ
Spencer, AP
Barnes, JF
Wynn, JE
Jones, CE
机构
[1] Med Univ S Carolina, Dept Pharm Practice, Coll Pharm, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Pharm Serv, Charleston, SC 29425 USA
[3] Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA
关键词
furosemide; human albumin solution; stability;
D O I
10.1345/aph.1A232
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To determine the chemical stability of furosemide in human albumin solution over a 28-day period and to assess admixtures for microbiologic contamination. METHODS: Samples were prepared by mixing furosemide injectable solution and 25% human albumin solution in a 1:1 molar ratio. Six bulk containers were prepared and stored in the dark: 3 under refrigeration (similar to4 degreesC) and 3 at room temperature (similar to25 degreesC). Study samples were withdrawn from each bulk solution immediately after preparation and at predetermined intervals over the subsequent 28 days. Containers were observed for color change and precipitation against a light and dark background at each sampling interval. Total furosemide concentration was determined using HPLC. Additional vials were prepared and assessed for microbiologic growth at time points corresponding with chemical stability results. RESULTS: A mean of 94.5% +/- 1.33% of the initial furosemide concentration remained after 48 hours at room temperature. Under refrigeration, 100.6% +/- 1.02% of the initial concentration remained at 14 days. Beyond these respective time points, <90% of the initial furosemide concentration remained. No bacterial or fungal growth was observed. CONCLUSIONS: When combined with 25% human albumin solution and stored under darkness, furosemide is chemically stable and free of microbiologic contamination for 48 hours at room temperature and 14 days under refrigeration.
引用
收藏
页码:423 / 426
页数:4
相关论文
共 11 条
[1]   DIURETIC EFFECT OF FRUSEMIDE IN PATIENTS WITH NEPHROTIC SYNDROME - IS IT POTENTIATED BY INTRAVENOUS ALBUMIN [J].
AKCICEK, F ;
YALNIZ, T ;
BASCI, A ;
OK, E ;
MEES, EJD .
BRITISH MEDICAL JOURNAL, 1995, 310 (6973) :162-163
[2]  
Chalasani N, 2001, J AM SOC NEPHROL, V12, P1010, DOI 10.1681/ASN.V1251010
[3]   Coadministration of albumin and furosemide in patients with the nephrotic syndrome [J].
Fliser, D ;
Zurbrüggen, I ;
Mutschler, E ;
Bischoff, I ;
Nussberger, J ;
Franek, E ;
Ritz, E .
KIDNEY INTERNATIONAL, 1999, 55 (02) :629-634
[4]   Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial [J].
Gentilini, P ;
Casini-Raggi, V ;
Di Fiore, G ;
Romanelli, RG ;
Buzzelli, G ;
Pinzani, M ;
La Villa, G ;
Laffi, G .
JOURNAL OF HEPATOLOGY, 1999, 30 (04) :639-645
[5]   DOSE-DEPENDENT PHARMACOKINETICS OF FUROSEMIDE IN THE RAT [J].
HAMMARLUND, MM ;
PAALZOW, LK .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1982, 3 (04) :345-359
[6]  
HAWS RM, 1993, PEDIATRICS, V91, P1142
[7]   MECHANISM OF FUROSEMIDE RESISTANCE IN ANALBUMINEMIC RATS AND HYPOALBUMINEMIC PATIENTS [J].
INOUE, M ;
OKAJIMA, K ;
ITOH, K ;
ANDO, Y ;
WATANABE, N ;
YASAKA, T ;
NAGASE, S ;
MORINO, Y .
KIDNEY INTERNATIONAL, 1987, 32 (02) :198-203
[8]  
KOKKO JP, 1996, CECIL TXB MED, P525
[9]  
Mattana J, 1996, NEPHRON, V73, P122
[10]  
*MICR, 2001, USP DI 2001, V1, P1266